Home   Package List   Routine Alphabetical List   Global Alphabetical List   FileMan Files List   FileMan Sub-Files List   Package Component Lists   Package-Namespace Mapping  
Info |  Source |  Caller Graph |  Entry Points |  Label References |  Local Variables |  Marked Items |  All
Print Page as PDF
Routine: SRTPUTL4

Package: Surgery

Routine: SRTPUTL4


Information

SRTPUTL4 ;BIR/SJA - RISK ASSESSMENT UTILITY ;05/15/08

Source Information

Source file <SRTPUTL4.m>

Caller Graph

Caller Graph Total: 1

Package Total Caller Graph
Surgery 1 SRTPUTLC  

Entry Points

Name Comments DBIA/ICR reference
BD ;;24^Alpha 1 Anti-Trypsin Deficiency^
BE ;;25^Bronchiectasis^
BF ;;26^Glomerular Sclerosis/Nephritis^
BG ;;27^Graft Failure^
BA ;;21^Acute Liver Failure^
BB ;;22^Lung Cancer^
BC ;;23^Alcoholic Cirrhosis^
AGG ;;177^Current Digoxin Use^
AGF ;;176^IV NTG within 48 Hours^
AGE ;;175^Congestive Heart Failure (CHF)^
AGD ;;174^Cerebral Vascular Disease^
BH ;;28^HBV Cirrhosis (Hepatitis B)^
BI ;;29^HCC (Hepatocellular CA)^
BJ ;;20^Acetaminophen Toxicity^
AFH ;;168^PAW Mean Pressure^
AGJ ;;170^Date of Death^
AGI ;;179^Preoperative Circulatory Device^
AGH ;;178^Current Diuretic Use^
AFI ;;169^FEV1 ^
ABH ;;128^Emphysema^
D ;;4^Recipient Height^
AGC ;;173^Number of Prior Heart Surgeries^
AGB ;;172^Prior MI^
GG ;;77^Donor Substance Abuse^
GF ;;76^COPD ^
GE ;;75^Liver Disease^
GD ;;74^Pulmonary Hypertension / Elevated PAP^
GC ;;73^Donor HLA-DR Typing^
GB ;;72^Donor HLA-DQ Typing^
GA ;;71^Elevated PAP^
AAA ;;111^Portal Vein Thrombosis^
GJ ;;70^Donor Date of Birth^
GI ;;79^History of Bleeding Esophageal and/or Gastric Varices^
GH ;;78^Porto Pulmonary Hypertension^
AHB ;;182^Transplant Type^
AHA ;;181^Assessment Status^
AHG ;;187^Date Started Dialysis^
AHD ;;184^Date Transmitted^
AHE ;;185^VA or Non-VA Indicator^
AHI ;;189^Tracheostomy^
AFD ;;164^PVR After Vasodilation^
ABB ;;122^Coma Greater than 24 Hours Postop (Y/N)^
HJ ;;80^Pre-Transplant Malignancy^
HH ;;88^History of Ascites^
HI ;;89^Total Ischemia Time for Organ^
AEE ;;155^Dilated Cardiomyopathy^
AED ;;154^Creatinine on Day of Transplant^
AEG ;;157^Ischemic Cardiomyopathy^
AEF ;;156^Coronary Artery Disease^
HB ;;82^History of Other Pre-Transplant Malignancy^
HC ;;83^Recipient Substance Abuse^
HA ;;81^History of Preop Transplant Skin Malignancy^
HF ;;86^Acute or Chronic Encephalopathy^
HG ;;87^Cold Ischemia Time for Organ^
HD ;;84^Active Infection for PSC^
HE ;;85^Warm Ischemia Time For Organ^
ABF ;;126^Return to Surgery within 30 days^
GET
AFE ;;165^LVEF % ^
ABG ;;127^Seizures^
I ;;9^IVIG Recipient^
ABI ;;129^Other Diagnosis^
AFF ;;166^PRA %^
C ;;3^VACO ID
AFG ;;167^PA Systolic Pressure^
EI ;;59^Diabetic Retinopathy^
EH ;;58^UNOS Status at time of Listing^
AFJ ;;160^Idiopathic Cardiomyopathy^
EJ ;;50^LAS Score at Listing^
EE ;;55^Biologic MELD score at transplant^
ED ;;54^MELD score at transplant^
EG ;;57^UNOS Status at time of Transplant^
EF ;;56^Bile Leak^
EA ;;51^LAS Score at Transplant^
AFA ;;161^Viral Cardiomyopathy^
EC ;;53^Biologic MELD score at listing^
EB ;;52^MELD Score at Listing^
AFB ;;162^Peripartum Cardiomyopathy^
AFC ;;163^PVR Before Vasodilation^
AJH ;;108^HIV + (positive)^
AJI ;;109^Post Transplant Prophylaxis for CMV/Antiviral Treatment^
ACC ;;133^Graft Failure Date^
ACB ;;132^Peripheral Vascular Disease^
ACA ;;131^Preop Functional Health Status^
ACG ;;137^Pancreatic Duct Anastomosis^
ACF ;;136^C-peptide at Time of Listing^
ACE ;;135^Glucose at Time of Listing^
ACD ;;134^Pancreas^
ACJ ;;130^New Mechanical Circulatory Support^
ACI ;;139^Amylase Post Transplant^
ACH ;;138^Glucose Post Transplant^
FA ;;61^Cardiac Disease (CAD, AF, EF<50%)^
FB ;;62^Inotrope Dependent Pre-Transplant^
FC ;;63^Medical Center Division^
FD ;;64^Donor HLA-A Typing^
FE ;;65^Donor HLA-B Typing^
FF ;;66^Donor HLA-C Typing^
FG ;;67^Donor HLA-BW Typing^
FH ;;68^Crossmatch D/R^
FI ;;69^Deceased Donor^
FJ ;;60^Diabetic Neuropathy^
AJC ;;103^Living Donor^
AIJ ;;190^Mediastinitis^
AAC ;;113^Lung Disease^
AJD ;;104^Donor with Malignancy^
AAB ;;112^Other Cardiomyopathy^
AJE ;;105^Primary Non-Function^
AJF ;;106^Secondary Sclerosing Cholangitis^
AAI ;;119^Cardiac Arrest Requiring CPR^
AJG ;;107^Toxic Exposure^
E ;;5^Recipient Weight^
CJ ;;30^HCV Cirrhosis (Hepatitis C)^
CI ;;39^Primary Sclerosing Cholangitis^
CH ;;38^Primary Biliary Cholangitis^
CC ;;33^Membranous Nephropathy^
CB ;;32^Interstitial Lung Disease^
CA ;;31^Donor Height^
CG ;;37^Polycystic Disease^
CF ;;36^Donor Weight^
CE ;;35^NASH ^
CD ;;34^Metabolic^
ADF ;;146^Transfusion >4 RBC Units^
ADG ;;147^Diabetes Mellitus^
ADD ;;144^PRA at Transplant^
ADE ;;145^Hypertension Requiring Meds^
ADB ;;142^Oral Hypoglycemics Required Post Transplant^
ADC ;;143^PRA at Listing^
ADA ;;141^Insulin Required Post transplant^
AAJ ;;110^Post Transplant Prophylaxis for PCP/Antibacterial Treatment^
ADJ ;;140^Lipase Post Transplant^
ADH ;;148^Reoperation for Bleeding^
ADI ;;149^Amiodarone Use^
AEA ;;151^Hyperlipidemia History^
AAH ;;118^On Ventilator > 48 Hours^
AEC ;;153^Prior Blood Transfusion^
AEB ;;152^Ventricular Tachycardia^
AAE ;;115^Active Infection Requiring Antibiotics^
AAD ;;114^Renal Impairment (Serum Creatinine >1.5)^
AAG ;;117^Pneumonia^
AAF ;;116^Bleeding/Transfusions^
DJ ;;40^Pulmonary Fibrosis^
DH ;;48^Donor ABO Blood Type^
DI ;;49^Donor CMV^
DF ;;46^Donor Age^
DG ;;47^Biliary Stricture^
DD ;;44^Donor Race^
DE ;;45^Donor Gender^
DB ;;42^Renal Cancer^
DC ;;43^Sarcoidosis^
DA ;;41^Pulmonary Hypertension^
AEI ;;159^Valvular Cardiomyopathy^
AEH ;;158^Alcoholic Cardiomyopathy^
AIG ;;197^Plasmapheresis^
AIA ;;191^Renal Failure Requiring Dialysis^
AIC ;;193^Operative Death^
AIB ;;192^Perioperative MI^
AEJ ;;150^Heparin Sensitivity^
TR
ABC ;;123^Superficial Incisional SSI^
AGA ;;171^Current Smoker^
AA ;;11^Date Placed on Waiting List^
ABA ;;121^Stroke/CVA^
AC ;;13^Recipient HLA-A Typing^
AB ;;12^Recipient CMV^
AE ;;15^Recipient HLA-C Typing^
AD ;;14^Recipient HLA-B Typing^
AG ;;17^Recipient HLA-DR Typing^
AF ;;16^Recipient HLA-BW Typing^
AI ;;19^Transplant Comments^
AH ;;18^Recipient HLA-DQ Typing^
ABJ ;;120^Psychosis^
AJ ;;10^Recipient ABO Blood Type^
ABD ;;124^Deep Incisional SSI^
II ;;99^Autoimmune Hepatitis^
IH ;;98^Obstructive Uropathy from BPH^
AJJ ;;100^Cryptogenic Cirrhosis^
IJ ;;90^Non-Compliance (Med and Diet)^
IA ;;91^On Methadone^
AJA ;;101^Chronic Rejection^
AJB ;;102^Hepatic Artery Thrombosis^
IB ;;92^Post Transplant Prophylaxis for TB/Antimycobacterial Treatment^
IE ;;95^IgA Nephropathy^
ID ;;94^Rejection^
IG ;;97^Lithium Toxicity^
IF ;;96^Calcineurin Inhibitor Toxicity^
ABE ;;125^Systemic Sepsis^

Label References

Name Line Occurrences
TR SRTPUTL4+4, SRTPUTL4+5

Local Variables

Legend:

>> Not killed explicitly
* Changed
! Killed
~ Newed

Name Field # of Occurrence
>> SRDT SRTPUTL4+5*, SRTPUTL4+6*, SRTPUTL4+7
>> SRFLD SRTPUTL4+4*, SRTPUTL4+5*
>> SRLR( SRTPUTL4+5*, SRTPUTL4+6
>> SRMM SRTPUTL4+4
>> SRP TR*
>> SRTPP SRTPUTL4+3, SRTPUTL4+4, SRTPUTL4+5
>> SRX( SRTPUTL4+4*, SRTPUTL4+7!
SRX1 SRTPUTL4+2~
SRXX SRTPUTL4+2~
>> SRYY( SRTPUTL4+3, SRTPUTL4+4, SRTPUTL4+5
>> SRZ SRTPUTL4+3*, SRTPUTL4+4, SRTPUTL4+5, SRTPUTL4+7*
>> SRZ1 SRTPUTL4+4*, SRTPUTL4+5*, SRTPUTL4+7*, TR
SRZZ SRTPUTL4+2~
>> X SRTPUTL4+4*, SRTPUTL4+5*, GET*

Marked Items

Name Field # of Occurrence
$T(@J GET
$T(@SRP SRTPUTL4+4, SRTPUTL4+5
Info |  Source |  Caller Graph |  Entry Points |  Label References |  Local Variables |  Marked Items |  All